Posters
« Back
The efficacy of Autologous Conditioned Serum (ACS) in patients with early osteoarthritis knee
EP28950
Poster Title: The efficacy of Autologous Conditioned Serum (ACS) in patients with early osteoarthritis knee
Submitted on 15 Aug 2018
Author(s): Dr.Madhan Jeyaraman (1), Prof.Ramesh.R (2)
Affiliations: (1) Post Graduate, (2) Professor
This poster was presented at IOACON 2017, Indore, Madhya Pradesh
Poster Views: 569
View poster »


Poster Information
Abstract: Introduction: Recently the idea of “Orthobiologics” leads to development of less invasive procedures and accelerated treatments which enhances functional recovery of musculoskeletal disorders. Percutaneous administration of substances with osteoinductive and osteogenic properties offers the advantage of decreased morbidity associated with classic techniques. The desired therapeutic effect of autologous conditioned serum (ACS) is facilitated by the ability of IL-1-Ra to limit the destructive inflammatory intra-articular (IA) actions of IL-1β. Objective: To investigate the effect of autologous conditioned serum (ACS) to reduce pain, improve joint function and enhance quality of life in patients with early knee osteoarthritis. Methods: Venous blood from 50 patients with symptomatic knee osteoarthritis was conditioned and injected into the affected joint as per treatment protocol. Each patient received a total of six ultrasound-guided IA injections at day 0, 7, 14, 60, 120, and 180 and followed for up to one year. Treatment outcome measures were assessed at each visit using Visual Analog Pain Scale (VAS), Knee Osteoarthritis Outcome Score (KOOS) and WOMAC score. Results: A total of 84% of patients reported better pain control at 6 months with 91% reporting improvement at 12 months. A statistically significant improvement is observed with WOMAC & KOOS score in knee osteoarthritis patients over 12 months. The overall reduction of pain and enhanced joint function was observed within 1 week and even 12 months after the initial injection. Conclusion: Autologous conditioned serum (ACS) has the potential to offer chondroprotective and molecular approach in treating pain and functionality in patients with mild and moderate knee osteoarthritis.Summary: The desired therapeutic effect of autologous conditioned serum (ACS), which is a potent orthobiologic, is facilitated by the ability of IL-1-Ra to limit the destructive inflammatory intra-articular (IA) actions of IL-1β. Autologous Conditioned Serum (ACS) has the potential to offer disease modifying, chondroprotective and biological & molecular approach in treating pain and functionality in patients with mild and moderate knee osteoarthritis.References: 1. Baltzer AWA, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis and Cartilage 2009; (17): 152-60.
2. Akedaa K, An HS, Okuma M. Platelet rich plasma stimulates porcine articular chondrocyte proliferation and matrix biosynthesis. Osteoarthritis Cartilage 2006; 14(12): 1272-80.
3. Gobbi A, Karnatzikos G, Mahajan V, Malchira S. Platelet rich plasma treatment in symptomatic patients with knee osteoarthritis: Preliminary results in a group of active patients. Sports Health. 2012 Mar;4(2):172-72.
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons